bullish
Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback
289 Views15 Jan 2022 23:01
SUMMARY
- Green Cross (006280 KS) is currently waiting for marketing approval from the FDA for its immune globulin intravenous injection, which will mark its entry into the U.S. market.
- The company will start commercializing its hemophilia A treatment, GreenGene F in China market this year. As a third-generation product, GreenGene is expected to gain substantial market share.
- Green Cross shares remained subdued last year, as the company could not finalize a contract manufacturing deal for COVID-19 vaccine.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback15 Jan 2022
- Okja: The Fight Between Netflix Vs. CJ CGV05 Jun 2017
- Netflix & Amazon Expand in Korea – Not a Coincidence20 Jan 2016
- Thoughts on Amazon –What Does Its Valuation Tells Us?01 Dec 2015
x